Lofarma S.p.A. lofarma.it


Public lists: Pharma Startups (4740)

nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route, the Methacholine Challenge Test, the Test Dose for foodstuff or additives allergy, and allergens adsorbed on single-use needles.

nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route...Show all

Company (Alive / Active)

Phone:

Fax:

Viale Cassala 40
20143
Italy

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Lofarma S.p.A. $0M Mar 19, 2019
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Lofarma S.p.A. Jobs

jobs by Indeed job
						search
There is no Investors data available for this company. Please select another tab.
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

VaxInnate Corporation

Cranbury, New Jersey, United States
Dead / InactiveVaxInnate is a privately-held biotechnology company in Cranbury, NJ that is developing a technology platform for use in developing novel and proprietary vaccines. VaxInnate's vaccines focus on infectious diseases, including seasonal and pandemic flu, dengue, and Clostridium difficile. VaxInnate's technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of vaccines. VaxInnate has already generated positive Phase 1, and in some instances Phase...Show allLogin to see details

Nuon Therapeutics

San Mateo, California, United States
Alive / ActiveNuon Therapeutics discovers novel uses for marketed drugs. The advantage of this approach is that the development program for the marketed indication will have investigated the compounds toxicity and established its tolerability. This makes it possible to proceed directly to clinical trials once the efficacy of the compound has been established in animal models. The costs and risks involved in the drug development process are greatly reduced. Tranilast is under development for the treatment of p...Show allLogin to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Hypoallergenic variants of mal d 1, the major allergen from malus domestica Jul 31, 2012 May 01, 2018 Patent
Hypoallergenic variants of phl p 5, the major allergen from Dec 18, 2012 Nov 07, 2017 Patent
Hypoallergenic variants of the major allergen from Dec 19, 2006 Feb 03, 2015 Patent
Allergens and allergoids from bee venom Dec 16, 2008 Jan 28, 2014 Patent
Hypoallergenic variants of the major allergen from Sep 16, 2008 Nov 26, 2013 Patent
See all 6 patents